COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY
Objective: To study the long-term results of the combined treatment of non-small cell lung cancer (NSCLC) using pre-surgery chemotherapy, radical surgery and personalized adjuvant chemotherapy based on the level of monoresistance genes. Methods: Four-year results of treatment of 72 patients of NS...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Avicenna Tajik State Medical University
2019-09-01
|
| Series: | Паёми Сино |
| Subjects: | |
| Online Access: | https://doi.org/10.25005/2074-0581-2019-21-3-420-425 |
| _version_ | 1797797503243911168 |
|---|---|
| author | E.O. RODIONOV S.V. MILLER L.A. EFTEEV S.A. TUZIKOV M.M. TSYGANOV I.V. DERYUSHEVA N.V. LITVYAKOV V.A. MARKOVICH U.B. URMONOV |
| author_facet | E.O. RODIONOV S.V. MILLER L.A. EFTEEV S.A. TUZIKOV M.M. TSYGANOV I.V. DERYUSHEVA N.V. LITVYAKOV V.A. MARKOVICH U.B. URMONOV |
| author_sort | E.O. RODIONOV |
| collection | DOAJ |
| description | Objective: To study the long-term results of the combined treatment of non-small cell lung cancer (NSCLC) using pre-surgery chemotherapy, radical surgery and personalized adjuvant chemotherapy based on the level of monoresistance genes.
Methods: Four-year results of treatment of 72 patients of NSCLC II-III stage were analyzed. All patients underwent 2 courses of neoadjuvant chemotherapy (vinorelbine/carboplatin) and surgical treatment. Personalized adjuvant chemotherapy based on the levels of expression of monoresistance genes АВСС5, RRM1, TYMS, TOP1, TOP2α, TUBB3, BRCA1, and ERCC1 was performed in the main group (n=35). Three courses of adjuvant chemotherapy (vinorelbine/carboplatin) were performed in the control group (n=37).
Results: In the main group the progression of the disease was observed in 14 out of 35, and in the control group – in 21 out of 37 patients. Relapsefree survival (RFS) in the main group was 60.0% (95% CI: 43.6-74.5), in the control group – 43.2% (95% CI: 28.7-59.1); Log-Rank test χ2 =3,071, р=0,080; RR=1,808 (95% CI: 0.918-3.561). The median RFS in the control group was 27 months (95% CI: 5.7-48.3). The overall survival rate in the main group was 77.1% (95% CI: 61.0-87.9), in the control group – 54.1% (95% CI: 38.4-69.0); Log-Rank test χ2 =2,813, p=0.094; RR=2,024 (95% CI: 0,870-4,709).
Conclusion: The developed method of personalized prescribing adjuvant chemotherapy to patients with NSCLC based on the molecular genetic characteristics of the tumor improves relapse-free and overall survival. |
| first_indexed | 2024-03-13T03:49:20Z |
| format | Article |
| id | doaj.art-ec05904d8e79461dbd1d23bc8b091b05 |
| institution | Directory Open Access Journal |
| issn | 2074-0581 2959-6327 |
| language | English |
| last_indexed | 2024-03-13T03:49:20Z |
| publishDate | 2019-09-01 |
| publisher | Avicenna Tajik State Medical University |
| record_format | Article |
| series | Паёми Сино |
| spelling | doaj.art-ec05904d8e79461dbd1d23bc8b091b052023-06-22T19:40:20ZengAvicenna Tajik State Medical UniversityПаёми Сино2074-05812959-63272019-09-0121342042510.25005/2074-0581-2019-21-3-420-425COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPYE.O. RODIONOV0S.V. MILLER1L.A. EFTEEV2S.A. TUZIKOV3M.M. TSYGANOV4I.V. DERYUSHEVA5N.V. LITVYAKOV6V.A. MARKOVICH7U.B. URMONOV8Department of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation. Department of Oncology, Siberian State Medical University, Tomsk, Russian FederationDepartment of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationDepartment of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationDepartment of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation. Department of Oncology, Siberian State Medical University, Tomsk, Russian FederationOncovirology Laboratory, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationOncovirology Laboratory, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationOncovirology Laboratory, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation. Institute of Biology, Ecology, Soil Science, Agriculture and Forestry, National Research Tomsk State University, Tomsk, Russian FederationDepartment of Thoracic Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationDepartment of Abdominal Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian FederationObjective: To study the long-term results of the combined treatment of non-small cell lung cancer (NSCLC) using pre-surgery chemotherapy, radical surgery and personalized adjuvant chemotherapy based on the level of monoresistance genes. Methods: Four-year results of treatment of 72 patients of NSCLC II-III stage were analyzed. All patients underwent 2 courses of neoadjuvant chemotherapy (vinorelbine/carboplatin) and surgical treatment. Personalized adjuvant chemotherapy based on the levels of expression of monoresistance genes АВСС5, RRM1, TYMS, TOP1, TOP2α, TUBB3, BRCA1, and ERCC1 was performed in the main group (n=35). Three courses of adjuvant chemotherapy (vinorelbine/carboplatin) were performed in the control group (n=37). Results: In the main group the progression of the disease was observed in 14 out of 35, and in the control group – in 21 out of 37 patients. Relapsefree survival (RFS) in the main group was 60.0% (95% CI: 43.6-74.5), in the control group – 43.2% (95% CI: 28.7-59.1); Log-Rank test χ2 =3,071, р=0,080; RR=1,808 (95% CI: 0.918-3.561). The median RFS in the control group was 27 months (95% CI: 5.7-48.3). The overall survival rate in the main group was 77.1% (95% CI: 61.0-87.9), in the control group – 54.1% (95% CI: 38.4-69.0); Log-Rank test χ2 =2,813, p=0.094; RR=2,024 (95% CI: 0,870-4,709). Conclusion: The developed method of personalized prescribing adjuvant chemotherapy to patients with NSCLC based on the molecular genetic characteristics of the tumor improves relapse-free and overall survival.https://doi.org/10.25005/2074-0581-2019-21-3-420-425non-small cell lung cancermonoresistance genespersonalized chemotherapy. |
| spellingShingle | E.O. RODIONOV S.V. MILLER L.A. EFTEEV S.A. TUZIKOV M.M. TSYGANOV I.V. DERYUSHEVA N.V. LITVYAKOV V.A. MARKOVICH U.B. URMONOV COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY Паёми Сино non-small cell lung cancer monoresistance genes personalized chemotherapy. |
| title | COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY |
| title_full | COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY |
| title_fullStr | COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY |
| title_full_unstemmed | COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY |
| title_short | COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY |
| title_sort | combined treatment of patients with non small cell lung cancer with personalized prescription of adjuvant chemotherapy |
| topic | non-small cell lung cancer monoresistance genes personalized chemotherapy. |
| url | https://doi.org/10.25005/2074-0581-2019-21-3-420-425 |
| work_keys_str_mv | AT eorodionov combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT svmiller combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT laefteev combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT satuzikov combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT mmtsyganov combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT ivderyusheva combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT nvlitvyakov combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT vamarkovich combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy AT uburmonov combinedtreatmentofpatientswithnonsmallcelllungcancerwithpersonalizedprescriptionofadjuvantchemotherapy |